The Protecting Veteran Access to Telemedicine Services Act of 2025 adds a new section to title 38 authorizing certain Department of Veterans Affairs health care professionals to deliver, distribute, or dispense prescription controlled substances to veterans through telemedicine without a prior in‑person examination, provided they hold an active state license, act in the usual course of professional practice, and the medication serves a legitimate medical purpose. The statute requires the VA Secretary to issue implementing regulations and expressly preserves obligations under the federal Controlled Substances Act.
This is a targeted expansion of VA telehealth authority: it narrows the change to VA employees and trainees (not contractors), ties prescriptive authority to state licensure and VA quality standards, and delegates operational detail to agency regulation. For compliance officers and VA leaders, the bill creates new regulatory, pharmacy‑logistics, and cross‑jurisdictional questions—especially around DEA registration, interstate practice, prescription‑monitoring, and controlled‑substance dispensing by mail or VA pharmacies.
At a Glance
What It Does
The bill amends title 38 by adding §1730D to permit covered VA health care professionals to use telemedicine to deliver, distribute, or dispense prescription controlled substances to eligible veterans without an in‑person exam when the clinician holds an active state license, practices within the usual course, and prescribes for a legitimate medical purpose. It requires the Secretary to issue regulations to govern the practice.
Who It Affects
Directly affects VA clinicians appointed under specified authorities (and VA health professions trainees under supervision), VA pharmacy operations, and veterans receiving care remotely. It explicitly excludes contractors and leaves community providers outside its scope unless employed by the VA.
Why It Matters
The bill creates a statutory pathway for the VA to offer controlled‑substance teleprescribing to veterans—potentially expanding access for rural, mobility‑limited, and mental‑health patients—while raising coordination questions with DEA rules, state licensing regimes, and existing controlled‑substance safeguards.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The new statute creates a precise carve‑out inside title 38 that lets VA employees use telemedicine to handle prescription controlled substances for veterans even if they have not performed an in‑person exam. That authority is conditional: the clinician must be a VA employee appointed under one of the listed authorities (or a trainee under supervision), must hold an active, full state license or meet Secretary‑set qualifications, must act within the usual course of professional practice, and must prescribe for a legitimate medical purpose.
The law does not itself rewrite federal controlled‑substances law. It starts from the premise that Compliance with the Comprehensive Drug Abuse Prevention and Control Act remains mandatory; the Secretary must issue regulations describing how telemedicine dispensing works inside VA practice.
Those implementing rules will need to address operational details the statute leaves unspecified—who can dispense (VA pharmacy vs. external pharmacy), how medicines are delivered or mailed, recordkeeping, PDMP reporting, DEA registration and electronic prescribing requirements, and safeguards against diversion.By limiting the authorization to VA employees and trainees, the bill keeps contractors and non‑VA community providers outside the new telemedicine authority. That design centralizes responsibility within VA systems—but also concentrates the implementation burden on the Department: IT, pharmacy logistics, training, quality monitoring, and coordination with state licensing boards and federal law enforcement will all require new processes.
The statute’s definitions clause imports the CSA’s statutory definitions for terms like “deliver” and “dispense,” and the bill’s rule of construction reminds readers that nothing in the provision eliminates CSA obligations—meaning DEA and other federal requirements remain binding.
The Five Things You Need to Know
The bill creates 38 U.S.C. §1730D authorizing covered VA health care professionals to use telemedicine to deliver, distribute, or dispense prescription controlled substances without an in‑person exam subject to conditions.
A covered health care professional must be a VA employee appointed under specified authorities (sections 7306, 7401, 7405, 7406, 7408 or under title 5), not a contractor, and must hold an active, full, unrestricted state license or meet Secretary‑set qualifications.
The statute explicitly includes health professions trainees appointed under section 7405 when they act under the clinical supervision of an authorized VA clinician.
The Secretary of Veterans Affairs must issue regulations establishing guidelines and a process for telemedicine dispensing within VA; the statute does not itself create operational rules.
The provision is expressly subject to the Comprehensive Drug Abuse Prevention and Control Act and contains a rule of construction that it does not relieve clinicians of their CSA obligations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the bill the "Protecting Veteran Access to Telemedicine Services Act of 2025." This is purely stylistic but signals the bill’s policy focus on access and telemedicine inside VA.
Telemedicine authority for controlled substances
Subsection (a) is the operative authorization: a covered VA clinician may use telemedicine to deliver, distribute, or dispense a prescription controlled substance without an in‑person exam if the clinician has an active state license, is acting in the usual course of practice, and prescribes for a legitimate medical purpose. Practically, this creates a statutory basis for VA to rely on telehealth for controlled substances but ties the clinician to state licensure standards and clinical‑practice norms.
Regulatory authority for the Secretary
Directs the Secretary to promulgate regulations that establish guidelines and a process for telemedicine dispensing. The delegation is broad and will govern operational issues—verification of patient identity, prescription routing, pharmacy dispensing method, recordkeeping, PDMP checking, and disciplinary processes—unless preempted by CSA or DEA rules.
Preserves Controlled Substances Act obligations
Provides a rule of construction that the new section does not remove or limit any obligation under the CSA. That preserves federal criminal and regulatory requirements (including DEA registration, labeling, and distribution rules) and signals that VA regulations must be consistent with federal controlled‑substance law.
Definitions and scope of covered clinicians
Defines key terms by referencing the CSA for words like “deliver” and “dispense,” and defines “covered health care professional” narrowly to VA employees appointed under listed authorities and trainees under supervision. Importantly, contractors are excluded, and clinicians must meet VA quality standards and license qualifications—shaping who may lawfully use the telemedicine pathway.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Rural and mobility‑limited veterans: Expands access to controlled‑substance treatment (pain management, mental‑health medications, medication‑assisted treatment) without travel to VA facilities, reducing travel burdens and missed care.
- VA clinicians and supervising preceptors: Gives VA providers a clearer statutory basis to treat veterans remotely with controlled drugs and allows trainees to participate under supervision, potentially improving continuity of care and training opportunities.
- VA system administrators and telehealth programs: Enables the VA to fold controlled‑substance management into existing telehealth services, potentially lowering patient no‑show rates and consolidating care within VA networks.
Who Bears the Cost
- Department of Veterans Affairs: Must develop and fund regulations, IT upgrades, pharmacy and mailing logistics, PDMP integration, training, and compliance/audit capacity to manage diversion risk and DEA requirements. This is a new implementation and oversight burden.
- VA pharmacies and logisticians: Increased responsibility for safe dispensing, packaging, secure mailing, chain‑of‑custody, and documenting controlled‑substance deliveries—potentially requiring new processes and staffing.
- State licensing boards and law enforcement: Will face more cross‑jurisdictional complaints, enforcement questions, and coordination demands if VA clinicians treat patients located in other states; boards may need to interpret scope‑of‑practice and remote‑practice standards.
Key Issues
The Core Tension
The central dilemma is access versus control: the bill advances veterans’ access to necessary controlled medications through telemedicine—especially for rural and mobility‑limited patients—while requiring the VA to preserve the centralized regulatory and enforcement safeguards needed to prevent diversion and misuse; achieving both aims demands detailed, often costly operational rules and tight federal‑state coordination, and there is no risk‑free way to reconcile rapid access expansion with strong abuse prevention.
The statute creates authority but punts most practical and legal detail to VA regulation while explicitly preserving the Controlled Substances Act. That split raises several unresolved implementation questions: whether and how VA will require DEA registration for prescribing clinicians (and how that interacts with state dispensing rules), how VA will report to state PDMPs, whether VA will permit mailing of schedules II–V drugs and under what security standards, and how the Department will verify patient location and state licensure when patients are in a different state than the prescriber.
The bill’s exclusion of contractors centralizes risk inside VA but also concentrates resource needs on the Department’s pharmacy and compliance infrastructure.
Operationally, the statute reduces a legal barrier to teleprescribing but increases reliance on the Secretary’s forthcoming regulations. That means access gains for veterans will depend on timely, detailed VA rules that align with DEA and state law; if those rules are delayed or conservative, the intended access benefits may be muted.
Conversely, aggressive regulatory implementation that prioritizes access could raise diversion and oversight risks if not paired with robust monitoring, PDMP integration, and enforcement coordination.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.